2nd Quarter Fiscal 2024

Earnings Conference
Call Presentation
February 7, 2024



SelectQuote

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: impacts of the COVID-19 pandemic and any other significant public health events; our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; our ability to regain and maintain compliance with NYSE listing standards; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on publications and other data obtained from third-party sources. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from such third-party sources.

No Offer or Solicitation; Further Information

This presentation is for informational purposes only and is not an offer to sell with respect to any securities. This presentation should be read together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the related notes thereto included in the Annual Report and subsequent quarterly reports.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this presentation Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. The most directly comparable GAAP measure is net income margin. We monitor and have presented in this presentation Adjusted EBITDA and Adjusted EBITDA Margin because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. For further discussion regarding these non-GAAP measures, please see today’s press release.

2Q FY2024 Earnings

- **Consolidated Company Highlights**
  - **Increasing FY24 financial guidance** midpoint for all metrics
  - Two consecutive quarters of **positive operating cash flow** on an LTM basis
  - On pace to deliver positive operating cash flow and **approach free cash flow breakeven** for fiscal year 2024

$ in millions	2Q24	2Q23	%
Revenue	**$405.4**	**$319.2**	**+27%**
Adjusted EBITDA*	**$67.4**	**$63.6**	**+6%**

- **Senior**
  - Two full years of **strong, stable operating performance** since executing strategic redesign
  - **Efficiency metrics in line** with 2Q fiscal 2023
  - Indicators point to continued **stability in customer retention** metrics
- **Healthcare Services**
  - Positive Adjusted EBITDA* for a **third consecutive quarter** despite significant investments
  - SelectRx nearing **63,000** members, far exceeding original forecast
  - **Increasing member and revenue growth outlook** for full fiscal year 2024

*See "Non-GAAP Financial Measures" above on slide 2

8th Consecutive Quarter Delivering Strong Results

Close Rates



Agent Productivity




AEP by the Numbers

MA Policies (YoY)	7%
Senior Revenue (YoY)	11%
Senior Adjusted EBITDA Margin*	32%
Tenured Agent Mix	~70%

*See "Non-GAAP Financial Measures" above on slide 2.

Senior Efficiency Metrics


Operating Expense Per Policy*



Marketing Expense Per Policy**




Revenue/CAC***



*Represents Senior operating costs divided by approved MA/MS policies.
**Represents Senior marketing costs divided by approved MA/MS policies.

***The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition costs for the Senior and Healthcare Services divisions, which represents the direct costs of acquiring leads.

FY24 Healthcare Services Outlook




	Original Guidance*	Revised Guidance
Member Growth	25%	40 - 50%
Total Revenue	~$375m (+50%)	$450m - $500m (+80 - 100%)
Adjusted EBITDA** Margins	Low Single Digits	Low Single Digits

*Original FY24 Guidance provided on September 13, 2023
**See "Non-GAAP Financial Measures" above on slide 2.

Consolidated Financial Summary


Revenue

$MM



Adjusted EBITDA*

$MM



*See "Non-GAAP Financial Measures" above on slide 2.

Senior Financial Summary

Revenue

$MM



Adjusted EBITDA*

$MM




*See "Non-GAAP Financial Measures" above on slide 2.


SelectQuote Senior KPIs

Total Policies Approved

000s




MA LTV




Healthcare Services KPIs

SelectRx Members




Revenue & Adjusted EBITDA*




*See "Non-GAAP Financial Measures" above on slide 2.

Rapid SelectRx Prescription Growth

Rx per Day*



Monthly Rx per Member




*Represents the total number of prescriptions shipped during the quarter divided by the number of business days in the quarter.

Life and Auto & Home


Revenue

$MM



Adjusted EBITDA*

$MM



*See "Non-GAAP Financial Measures" above on slide 2.

Revised FY24 Financial Guidance

REVENUE	**$1.23B** to **$1.30B** from $1.05 billion to $1.20 billion*	**+26% YoY** **At the Midpoint**
ADJUSTED EBITDA**	**$90m** to **$105m** from $80 million to $105 million*	**+31% YoY** **At the Midpoint**
NET LOSS	**($45)m** to **($22)m** from $(50) million to $(22) million*	**+43% YoY** **At the Midpoint**

*Original FY24 Guidance provided on September 13, 2023
**See "Non-GAAP Financial Measures" above on slide 2.

Supplemental Information

Net Loss to Adjusted EBITDA Reconciliation

	2Q FY 2024					
(in thousands)	Senior	Healthcare Services	Life	Auto & Home	Corp & Elims	Consolidated
Revenue	$ 247,529	$ 111,710	$ 37,367	$ 10,487	$ (1,655)	$ 405,438
Operating expenses	(168,816)	(108,729)	(32,798)	(5,762)	(21,919)	(338,024)
Other income (expense), net	—	—	—	—	—	—
Adjusted EBITDA	78,713	2,981	4,569	4,725	(23,574)	67,414
Share-based compensation expense						(3,822)
Transaction costs						(2,400)
Depreciation and amortization						(5,898)
Loss on disposal of property, equipment, and software						—
Interest expense, net						(24,415)
Income tax expense						(11,487)
Net income						$ 19,392

	2Q FY 2023					
(in thousands)	Senior	Healthcare Services	Life	Auto & Home	Corp & Elims	Consolidated
Revenue	$ 223,826	$ 55,480	$ 33,995	$ 7,808	$ (1,921)	$ 319,188
Operating expenses	(140,209)	(64,781)	(28,152)	(5,524)	(16,877)	(255,543)
Other income (expense), net	—	—	—	—	(70)	(70)
Adjusted EBITDA	83,617	(9,301)	5,843	2,284	(18,868)	63,575
Share-based compensation expense						(2,936)
Transaction costs						(442)
Depreciation and amortization						(7,188)
Loss on disposal of property, equipment, and software						(46)
Interest expense, net						(21,044)
Income tax expense						(9,405)
Net income						$ 22,514

Net Loss to Adjusted EBITDA Reconciliation (FY24 Guidance)

(in thousands)	Range	
Net loss	$ (45,000)	$ (22,000)
Income tax benefit	(8,000)	(4,000)
Interest expense, net	97,000	92,000
Depreciation and amortization	24,000	22,000
Share-based compensation expense	15,000	12,000
Non-recurring expenses	7,000	5,000
Adjusted EBITDA	$ 90,000	$ 105,000



SelectQuote Inc.
6800 West 115th Street
Suite 2511
Overland Park, Kansas 66211
Phone: (913) 599-9225

Investor Relations
investorrelations@selectquote.com